Neurocrine Biosciences Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2016 | — | $314.9M | $83.3M |
| FY2017 | — | $372.2M | $254.7M |
| FY2018 | — | $480.8M | $141.7M |
| FY2019 | — | $636.9M | $112.3M |
| FY2020 | — | $1.13B | $187.1M |
| FY2021 | — | $1.37B | $340.8M |
| FY2022 | — | $1.71B | $262.9M |
| FY2023 | — | $2.23B | $251.1M |
| FY2024 | — | $2.59B | $233.0M |
| FY2025 | — | $3.25B | $713.0M |